The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the potential efficacy of JNJ-42165279 in treating anxiety disorders through evaluation of brain activation patterns using imaging technology in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Janssen Research & Development, LLC
• Treatments: JNJ-42165279

Criteria

Inclusion criteria

• Good general health

• Body mass index between 18 and 30 kg/m2 and body weight not less than 50 kg

• Must adhere to required contraception during and for 3 months after study

• Must agree to not donate sperm during and for 3 months after study

• Must agree to not donate blood during and for 1 month after study

• Able to speak and understand English fluently

Exclusion criteria:

• Clinically significant medical or psychiatric illness

• Any contraindication to magnetic resonance imaging

• Unable to pass hearing test

• Alcohol or substance abuse; excessive nicotine or caffeine use

• Recently received an investigational drug, vaccine, or invasive medical device

• Unable to abide by protocol restrictions on use of other medications